These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33832803)

  • 1. The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson's disease.
    Muñoz SS; Petersen D; Marlet FR; Kücükköse E; Galvagnion C
    Biophys Chem; 2021 Jun; 273():106534. PubMed ID: 33832803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type GBA1 increases the α-synuclein tetramer-monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice.
    Glajch KE; Moors TE; Chen Y; Bechade PA; Nam AY; Rajsombath MM; McCaffery TD; Dettmer U; Weihofen A; Hirst WD; Selkoe DJ; Nuber S
    Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase and Parkinson disease: Recent advances.
    Schapira AH
    Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
    Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
    Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
    Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
    Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation.
    Galvagnion C; Marlet FR; Cerri S; Schapira AHV; Blandini F; Di Monte DA
    Brain; 2022 Apr; 145(3):1038-1051. PubMed ID: 35362022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
    Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
    Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson's Disease.
    Cerri S; Ghezzi C; Ongari G; Croce S; Avenali M; Zangaglia R; Di Monte DA; Valente EM; Blandini F
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672321
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Smith L; Schapira AHV
    Cells; 2022 Apr; 11(8):. PubMed ID: 35455941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
    Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
    Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saposin C protects glucocerebrosidase against α-synuclein inhibition.
    Yap TL; Gruschus JM; Velayati A; Sidransky E; Lee JC
    Biochemistry; 2013 Oct; 52(41):7161-3. PubMed ID: 24070323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
    Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
    Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease.
    Seo BA; Kim D; Hwang H; Kim MS; Ma SX; Kwon SH; Kweon SH; Wang H; Yoo JM; Choi S; Kwon SH; Kang SU; Kam TI; Kim K; Karuppagounder SS; Kang BG; Lee S; Park H; Kim S; Yan W; Li YS; Kuo SH; Redding-Ochoa J; Pletnikova O; Troncoso JC; Lee G; Mao X; Dawson VL; Dawson TM; Ko HS
    Neuron; 2021 Dec; 109(23):3758-3774.e11. PubMed ID: 34644545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
    Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
    Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome.
    Ruz C; Barrero FJ; Pelegrina J; Bandrés-Ciga S; Vives F; Duran R
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.